AVXL · Anavex Life Sciences Corp
United States · RS rating 5 · As of 2026-11-03
| Price | 1.20 USD |
|---|---|
| 1-day change | +5.3% |
| RS rating (overall / 1M / 3M / 12M) | 5 / 14 / 5 / 7 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 28 / 5 / 51 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +45.5% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +84.5% |
| Market cap (USD) | $306.7M |